Ardent Health Shares Plunge 33% Following Revenue Adjustment Over Receivables

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Ardent Health shares plunged 33% after revealing a $43 million revenue adjustment due to overstated receivables. A securities fraud lawsuit was filed over misleading accounting disclosures.

Ardent Health Shares Plunge 33% Following Revenue Adjustment Over Receivables

Ardent Health Services (NYSE:ARDT) experienced a significant stock decline after disclosing material accounting changes related to accounts receivable reserves. The company revealed that it had previously overstated the collectability of receivables by employing a simplified 180-day reserve methodology rather than the more rigorous historical collection analysis it had previously represented to investors.

The accounting correction resulted in a $43 million revenue adjustment and prompted the company to increase professional liability insurance reserves by $54 million. These charges reflect both the direct impact of the accounting restatement and anticipated costs related to potential litigation exposure stemming from the disclosure.

A securities fraud class action lawsuit has been initiated against the company. Investors who held shares during the relevant period and sustained losses are being notified of their rights under the pending litigation. The case centers on allegations that the company's prior disclosures regarding its accounts receivable accounting methodology were materially misleading.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 21

Related Coverage

GlobeNewswire Inc.

Plug Power Faces Class Action Over DOE Loan Claims as April Deadline Looms

Plug Power faces class action lawsuit alleging false statements about DOE loans and hydrogen facilities. Investors have until April 3, 2026 to apply as lead plaintiffs.

PLUG
GlobeNewswire Inc.

BlackRock TCP Capital Hit by Class Action Over $19B NAV Collapse

BlackRock TCP Capital faces class action lawsuit after 19% NAV decline and 12.97% stock plunge. Investors must act by April 6 deadline.

TCPC
GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
GlobeNewswire Inc.

Class Action Lawsuit Filed Against China Liberal Education Over Alleged $300M Pump-and-Dump Scheme

Class action lawsuit filed against China Liberal Education Holdings for alleged pump-and-dump scheme coordinating with scammers, resulting in $300M+ investor losses.

CLEUF
GlobeNewswire Inc.

METC Faces Class Action Over Brook Mine Claims; Lead Plaintiff Deadline Set for March 31

Ramaco Resources faces class action lawsuit over alleged false Brook Mine operational claims, with lead plaintiff deadline set for March 31, 2026.

METCMETCBMETCI
GlobeNewswire Inc.

Disc Medicine Stock Collapses on FDA Rejection; Law Firm Probes Securities Fraud

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.

IRON